Catalyst Pharmaceuticals (CPRX) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
8 Jul, 2026Opening remarks and agenda
Meeting commenced with instructions for participation and a welcome from the board chair.
Agenda included voting on three specific proposals as outlined in the proxy statement.
Board and executive committee updates
Introductions of all board members and executive officers were made at the start of the meeting.
Corporate governance
The chairperson was authorized to preside and set meeting procedures per the company's bylaws.
The record date for voting was set as June 3, 2026, and all required notices and proxy materials were confirmed as mailed.
Inspector of Election was appointed and sworn in, with responsibilities for vote canvassing and reporting.
Quorum was confirmed with a majority of shares represented.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Catalyst Pharmaceuticals
- Strong growth in rare disease portfolio, robust cash, and strategic expansion plans for 2026.CPRX
Barclays 28th Annual Global Healthcare Conference8 Jul 2026 - Record revenue and net income growth in 2024, with strong 2025 outlook and robust cash position.CPRX
Q4 20248 Jul 2026 - Q1 2025 revenue surged 43.6% to $141.4M, led by FIRDAPSE and AGAMREE growth.CPRX
Q1 20258 Jul 2026 - DMD therapies advance with novel delivery, regulatory support, and key data expected in Q1.CPRX
Citi's 2024 Global Healthcare Conference8 Jul 2026 - Q3 revenue up 25.3% year-over-year, with raised guidance and strong cash reserves.CPRX
Q3 20248 Jul 2026 - Shareholders will vote on a merger with Angelini Pharma amid legal scrutiny and executive retention plans.CPRX
Proxy filing30 Jun 2026 - Shareholders to vote on $31.50/share cash merger with Angelini Pharma, board recommends approval.CPRX
Proxy filing8 Jun 2026 - Shareholders to vote on a $31.50/share cash merger with Angelini Pharma, unanimously backed by the board.CPRX
Proxy filing28 May 2026 - Merger with Angelini Pharma announced; Q1 2026 revenues up 28.2% to $149.4 million.CPRX
Proxy filing12 May 2026